EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma

Sedigheh Givi, Benedikt J Lohnes iD, Saber Ebrahimi, Sophie Riedel, Sneha Khokhali, Shamsul A Khan, Maximilian Keller iD, Catherine Wölfel, Hakim Echchannaoui, Ernesto Bockamp, Maya C Andre, Hinrich Abken iD und 2 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sedigheh Givi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany. Hauptthemen laut MEDLINE: Melanoma, CRISPR-Cas Systems, Immunotherapy, Adoptive, B7 Antigens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm-Sander-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapy directed to CD19 and B-cell maturation antigen has revolutionized treatment of B-cell leukemia and lymphoma, and multiple myeloma. However, identifying suitable targets for acute myeloid leukemia (AML) remains challenging due to concurrent expression of potential target antigens on normal hematopoietic stem cells or tissues. As the stress-induced B7H6 molecule is rarely found on normal tissues but expressed on many cancers including AML and melanoma, the NKp30-ligand B7H6 emerges as a promising target for NKp30-based CAR T therapy for these tumors. In this study, we report a comprehensive B7H6 expression analysis on primary AML and melanoma as well as on different tumor cell-lines examined by RT-qPCR and flow cytometry, and efficient anti-tumor reactivity of NKp30-CAR T cells to AML and melanoma. To overcome limitations of autologous CAR T-cell fitness-dependent efficacy and patient-tailored production, we generated CRISPR/Cas9-mediated TCR-knockout (TCRKO) NKp30-CAR T cells as an off-the-shelf approach for CAR T therapy. Functional studies comparing NKp30-CD28 CAR or NKp30-CD137 CAR TCR+ and TCRKO T lymphocytes revealed superior anti-tumoral immunity of NKp30-CD28 CAR TCRKO T cells to AML and melanoma cell lines in vitro, and effective control of tumor burden in an NSG melanoma-xenograft mouse model. In conclusion, these findings highlight the therapeutic potential of NKp30 CAR TCRKO T cells for adoptive T-cell therapy to B7H6-expressing cancers, including melanoma and AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaCRISPR-Cas SystemsImmunotherapy, AdoptiveB7 AntigensNatural Cytotoxicity Triggering Receptor 3Receptors, Chimeric AntigenT-LymphocytesLeukemia, Myeloid, AcuteReceptors, Antigen, T-CellAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

B7H6 expressing tumorsCAR T-cell therapyNKp30-based CAR T-cell therapyacute myeloid leukemiaimmunotherapymelanoma

Substanzen

B7 AntigensNatural Cytotoxicity Triggering Receptor 3Receptors, Chimeric AntigenNCR3 protein, humanReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
  • Research Center for Immunotherapy, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
  • Partner Site Frankfurt/Mainz, German Consortium for Translational Cancer Research (DKTK), 55101 Mainz, Germany.
  • Institute for Translational Immunology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
  • Department of Hematology/Oncology and General Pediatrics, Children's University Hospital, University of Tübingen, 72074 Tübingen, Germany.
  • Department of Pediatric Intensive Care, Children's University Hospital, 4031 Basel, Switzerland.

ORCID-Profile: Benedikt J Lohnes, Maximilian Keller, Hinrich Abken, Matthias Theobald, Udo F Hartwig

Förderung

  • Wilhelm-Sander-Stiftung

Zitieren

APA

Givi, S., Lohnes, B. J., Ebrahimi, S., Riedel, S., Khokhali, S., Khan, S. A., Keller, M., Wölfel, C., Echchannaoui, H., Bockamp, E., Andre, M. C., Abken, H., Theobald, M., & Hartwig, U. F. (2025). CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178235

Vancouver

Givi S, Lohnes BJ, Ebrahimi S, Riedel S, Khokhali S, Khan SA, et al. CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178235

BibTeX
@article{Givi2025,
  author = {Givi, Sedigheh and Lohnes, Benedikt J and Ebrahimi, Saber and Riedel, Sophie and Khokhali, Sneha and Khan, Shamsul A and Keller, Maximilian and Wölfel, Catherine and Echchannaoui, Hakim and Bockamp, Ernesto and Andre, Maya C and Abken, Hinrich and Theobald, Matthias and Hartwig, Udo F},
  title = {CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178235}
}
Kostenlos starten →